Liver Benefits: Combating Fatty Liver Disease Fatty liver disease, especially non-alcoholic steatohepatitis (NASH) , is on the rise and closely linked to obesity and insulin resistance
Cell culture studies using adipocytes have shown that NNMT overexpression promotes lipid accumulation and insulin resistance, while NNMT knockdown or inhibition increases NAD+ levels, activates SIRT1, enhances mitochondrial respiration, promotes expression of thermogenic genes including UCP1, and drives white adipocyte browning toward a beige phenotype
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
Our team is investigating claims on behalf of those impacted by ultra-processed foods and seeking compensation for victims of deceptive practices
Notably, in the third trajectory, the ECD-TMD interactions are disrupted after 100 ns, the motions of the ECD are quite large in the range of 100700 ns (the C r.m.s.d
Davidian, J
